Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing agreement with the Trump ...

The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

Hetlioz (tasimelteon) has been approved in the US for a few years to treat sleep disorders affecting people who are blind or ...

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

Judges in the First US Circuit Court of Appeals in Boston have rejected an effort to overturn last month's injunction on the ...

OpenAI has announced ChatGPT Health, which promises to bring users' medical records and health and wellness apps like Apple ...